• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Oncology

Sequencing of androgen-deprivation therapy with radiotherapy for non-metastatic prostate cancer

byDaniel GoldshteinandSze Wah Samuel Chan
December 28, 2022
in Oncology, Urology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Concurrent/adjuvant androgen-deprivation therapy has improved metastatic-free survival compared to neoadjuvant/concurrent androgen-deprivation therapy.

2. The statistical significance was mainly seen in patients who had prostate-only radiation, and not seen in patients who had whole-pelvis radiation.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Androgen-deprivation therapy (ADT) when added to radiotherapy (RT) has been shown to improve survival for localized prostate cancer, but the optimal sequencing of ADT has not been determined. This study contains pooled data from 12 randomized trials to examine whether neoadjuvant/concurrent or concurrent/adjuvant ADT leads to better outcomes. The primary endpoints were metastatic-free survival (MFS), and secondary endpoints included overall survival (OS), biochemical recurrence (BCR), distant metastasis (DM), prostate cancer specific mortality (PCSM), and other-cause mortality. Not all patient characteristics were equal in both groups as it was found that the concurrent/adjuvant ADT group had higher levels of high-risk disease than in the neoadjuvant/concurrent ADT group. The study also analyzed subgroups of RT and found that there were differences in patients who received prostate-only RT (PORT) and those who received whole-pelvis RT (WPRT). This study found that in the whole population, the concurrent/adjuvant ADT group had improved MFS (64.9% vs 61.4% in 10-year estimate), BCR (27.5% vs 33.7%), PCSM (6.5% vs 7.7%), and OS (68.8% vs 64.7%) than patients in the neoadjuvant/concurrent ADT group, but the statistical significance was only seen in the PORT group. The strengths of this study include the large population size, the number of studies, and the subgroup analysis. Limitations of this study include a non-homogeneous baseline characteristic. Overall, this study suggests that concurrent/adjuvant ADT is the optimal sequence for prostate-only radiation.

Click to read the study in JCO

Relevant Reading: Prostate Radiotherapy With Adjuvant Androgen Deprivation Therapy (ADT) Improves Metastasis-Free Survival Compared to Neoadjuvant ADT: An Individual Patient Meta-Analysis

In-Depth [meta-analysis]: This study contains 7,409 patients from 12 randomized trails that enrolled patients receiving neoadjuvant/concurrent (started more than 2 months prior to RT) or concurrent/adjuvant (started with RT and used for more than 2 months after finishing RT) short term ADT (4-6 months) with RT. Analysis was conducted on an intention-to-treat basis. Median follow-up time was 10.2 years. Patients (1,084) in the concurrent/adjuvant ADT group a more often had high-risk disease than patients (6,325) in the neoadjuvant/concurrent ADT group. The study found that overall, patients in the concurrent/adjuvant ADT group had improved MFS than patients in the neoadjuvant/concurrent ADT group, with 10-year estimates of 64.9% v 61.4% (95%CI, 0.74 to 0.93), but this was mainly seen in patients receiving PORT who had a HR 0.65 (95%CI, 0.54 to 0.79), compared to those who had WPRT (HR 0.94, 95%CI, 0.79 to 1.12). Overall, concurrent/adjuvant ADT was also associated with improved BCR (27.5% vs 33.7%, 95% CI, 0.68 to 0.87), PCSM (6.5% vs 7.7%, 95% CI, 0.59 to 0.99), and OS (68.8% vs 64.7%, 95% CI, 0.70 to 0.89), but when further analyzed, the statistical significance was mostly seen in patient with PORT and not in patient with WPRT. There were no overall significant differences in DM observed (12.0% vs 10.2%, 95% CI, 0.95 to 1.39), but in patients with WPRT there was an associated increase in incidence of DM. Overall this study found that concurrent/adjuvant ADT is associated with better outcomes, but only in those patients who receive prostate-only radiation.

RELATED REPORTS

Pelvic lymph node radiotherapy and androgen deprivation therapy augment progression-free status following prostatectomy

Abiraterone plus prednisone improves survival in patients with de novo metastatic castration-sensitive prostate cancer

Bone mineral density testing beneficial for older men receiving androgen deprivation therapy for localized or regional prostate cancer

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: androgen deprivation therapy (ADT)non-metastatic prostate cancerprostate cancer radiation
Previous Post

Apixaban is superior to rivaroxaban in patients with atrial fibrillation and valvular heart disease

Next Post

Neonatal docosahexaenoic acid supplementation is associated with higher IQ scores at five years of age

RelatedReports

Patient-reported outcomes differ significantly based on treatment in prostate cancer: The ProtecT trial
Chronic Disease

Pelvic lymph node radiotherapy and androgen deprivation therapy augment progression-free status following prostatectomy

May 24, 2022
Patient-reported outcomes differ significantly based on treatment in prostate cancer: The ProtecT trial
Chronic Disease

Abiraterone plus prednisone improves survival in patients with de novo metastatic castration-sensitive prostate cancer

May 11, 2022
Repeat bone mineral density testing may not improve prediction of fracture outcomes
Chronic Disease

Bone mineral density testing beneficial for older men receiving androgen deprivation therapy for localized or regional prostate cancer

April 5, 2022
Testosterone replacement in male cancer survivors helps improve body composition
Chronic Disease

Abiraterone acetate improves survival in high-risk non-metastatic prostate cancer

February 8, 2022
Next Post
Large proportion of late preterm infants and older admitted to the NICU

Neonatal docosahexaenoic acid supplementation is associated with higher IQ scores at five years of age

Neurocognitive deficits in congenital heart disease may not worsen with age

Vitamin D3 supplementation not effective in preventing ventricular hypertrophy

Tenofovir disoprovil fumarate HIV prophylaxis linked with minimal kidney impact

Religiosity and spirituality may positively impact the well-being of kidney transplant recipients

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Stroke may be associated with sleep disturbances in adults
  • Transcarotid artery revascularization not associated with a significant difference in 30-day risk of stroke, death and myocardial infarction compared to carotid endarterectomy
  • Drinking characteristics in adolescence predict alcohol behaviors in early adulthood
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options